Airbnb, Inc. vs ARK Genomic Revolution ETF — how do they compare? Airbnb, Inc. trades at $180.65 (market cap $110.76B), while ARK Genomic Revolution ETF trades at $44.48. Which is the better fit depends on your goals.
| ABNB | ARKG | |
|---|---|---|
Market Cap | $110.76B | — |
Sector | Consumer Cyclical | Sector/Thematic |
52-Week High | $184.98 | $44.55 |
52-Week Low | $111.54 | $24.02 |
Enterprise Value | $101.19B | — |
Signals from Pluang's Aura AI — not financial advice
ABNB trades at $180.06, down 2.51% today but remains near recent highs following strong Q2 2026 earnings that beat expectations. The stock shows bullish technical momentum with moving averages supporting upward trends, though oscillators indicate potential overbought conditions. Fundamentally, Airbnb demonstrates robust revenue growth with $12.24B in 2025 revenue and impressive 82.9% gross margins, though valuation multiples remain elevated with a P/E of 42.23. Recent news highlights the company's strategic pivot toward AI integration and expansion into hotel listings and travel services.
The outlook remains positive with analyst consensus leaning toward Buy (46.7% of ratings) and a $173.26 price target, though current price exceeds this consensus. Key opportunities include AI-driven efficiency gains and travel demand recovery, while risks involve premium valuation sensitivity and competitive pressures in the evolving travel marketplace. Institutional sentiment appears cautiously optimistic given recent earnings momentum.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →